Global Partnerships
SK bioscience has established a broad product portfolio and continues to invest in vaccine research,
which will be the driving force in the future life science business going forward.
We will develop premium vaccines based on state-of-the-art technology and contribute to the promotion of public health.
which will be the driving force in the future life science business going forward.
We will develop premium vaccines based on state-of-the-art technology and contribute to the promotion of public health.
SK bioscience has established partnerships with various global pharmaceutical companies and institutions around the world, including in the United States, United Kingdom, France, Switzerland, Norway and Australia.
- USA : Novavax, PATH (a catalyst for global health), Bill & Melinda Gates Foundation, University of Washington, MSD
- UK : AstraZeneca, GSK Glaxo SmithKline
- France : Sanofi Pasteur
- Switzerland : International Vaccine Institute
- Norway : CEPI
- Australia : CSL